logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Dendreon Priced To Go Out of Business

  +Follow August 23, 2013 4:12PM
Share:
Tickers Mentioned:

An analyst at Deutsche Bank downgraded Dendreon Corp. (DNDN) on Aug. 23, lowering the price target on the biotech company all the way to $1 a share. The bank noted that Dendreon has posted disappointing sales of their prostate cancer treatment drug Sipuleucel-T  (trade name Provenge) and is accumulating massive debt, and is in trouble of going under completely.

Duetsche's assessment of the Seattle, Wa.-based biotech was dire. In a note to investors, analyst Robyn Karnauskas wrote, “Per our calculations, even if there is drastic restructuring and significant cost cuts, spending may still outpace [revenue] growth in the near term. Consequentially, we believe that the terms of a debt refinancing may have a negative impact on equity holders.” The company downgraded Dendreon to “sell.” Deutsche had previously held a $6 price target for the stock.

Following Dendreon’s dismal second quarter earnings on Aug. 17, Wedbush Securities analyst David Nierengarten was even more pessimistic than Deutsche, and put his price target of the company at zero. That is, the only option for the troubled company is to file for bankruptcy.

Nierengarten said the company’s flagship product Provenge has always been doomed, as it is too expensive to produce and turn a profit, and thus Dendreon stands no chance of survival.

Dendreon was priced as high as $57.67 a share in April 2010 following the FDA approval of Provenge, and the stock hovered between $30 and $40 until Aug. 4, 2011. On that date the company abandoned its forecast for Provenge, and the stock fell 66 percent that day, and has continued plummeting since.

Dendreon dropped 9.72 percent on the poor analyst forecast to hit $2.88 a share, the lowest the stock has been in over four years.

(image courtesy of Flickr)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for dndn
StockTalk
30 Jun 15 10:46:29
$MNKD need a good break of 200dma prob next $DNDN
Will Kelly
29 Jun 15 14:41:07
@Mazmasta @AjTrader7 What $DNDN call?
E B
29 Jun 15 11:46:33
.@AjTrader7 thanks for proving my point. What about ur $DNDN buy after they went bankrupt at .22 and sold at like .16? Nice one there! -30%
DeadCatBill
29 Jun 15 04:25:49
@bradloncar The 800 million $DNDN took on worked out so well
Penny Stock Secret
28 Jun 15 22:36:35
The Most Accurate Stock Alert Service Made $240,000 Yesterday http://t.co/NovWYe2RAx .. $DNDN $NAII $VOXX
DailyStockPicks
27 Jun 15 18:04:52
$OCLS strong buy price target of $3 upgraded by Maxim. 100%+ upside $GES $HCC $FOLD $NTEK $DNDN $DNDNQ investors read http://t.co/radWvM4IEG
Joseph Hopkins
26 Jun 15 16:52:15
@dzstep Yeah baby, use it for a vacation. I got burnt on $DNDN; biggest lost I've ever had. Watch $AAVL; people are buying it - STAY AWAY!
Joseph Hopkins
26 Jun 15 16:46:33
@dzstep Dude, please don't go there. $CLDN will be pulling a $DNDN very soon. I'll take your money if you don't want it!
RG Capital
25 Jun 15 12:00:28
@redacre I still think valuation too pie in the sky. 5 patients right? Reminds me of $dndn when optimism was too high.
Joe
24 Jun 15 20:32:06
@Hedge_FundGirl Must be the name. John Johnson ruined plenty of companies too--not related. #imclone #savient $dndn http://t.co/m1jkhAhBEs
Penny Stock Secret
21 Jun 15 23:08:12
Yesterday We Made $94,000 In Just One Trade More Info Here http://t.co/NovWYe2RAx .. $DNDN $NAII $VOXX
				
				
  +Follow August 23, 2013 4:12PM
Share:

Comments

 

blog comments powered by Disqus

 

 Today's Must Reads

Microsegmentation: The Future of Cybersecurity?


How this Playboy Playmate Became a Better Stock Trader Than You

Long Term Rates Are On The Up…What’s Next?

The Modern Web: So Many Ways to Invest in Wireless Mobile Stocks

It's Time for the Rest of the Country to Legalize Weed

 

Do you expect a 10% correction by the end of 2015? in Equities.com Polls on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN